Alamar Biosciences Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended June 30, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _______________to ____________Commission File Number: 001-43235 Alamar Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) 36-4899036(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 47071 Bayside ParkwayFremont, California(Address of principal executive offices) Registrant’s telephone number, including area code: (510) 626-9888 Securities registered pursuant to Section 12(b) of the Act: The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒ Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒As of July 31, 2026, the registrant had 69,392,766 shares of common stock, $0.0001 par value per share, outstanding. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that are based on our management’s beliefs andassumptions and on information currently available to our management. All statements, other than statements of historical factscontained in this Quarterly Report on Form 10-Q, including statements regarding our future financial condition, business strategyand plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identifyforward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,”“may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or othercomparable terminology, although not all forward-looking statements contain these words. These forward-looking statements involve risks, uncertainties and other factors that may cause our actual results, levels of activity,performance or achievements to be materially different from the information expressed or implied by these forward-lookingstatements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this QuarterlyReport on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by usand our projections of the future, about which we cannot be certain. Forward-looking statements in this Quarterly Report on Form10-Q include, but are not limited to, statements about: •estimates of our addressable market, market growth, future revenue, expenses, capital requirements and our needs foradditional financing;•our expectations regarding the potential benefits of our strategy;•our expectations regarding the timing of potential regulatory submissions;•our expectations regarding the rate and degree of market acceptance of our products;•competitive companies and technologies and our industry;•our ability to manage and grow our business and develop and commercialize new products;•our ability to establish and maintain intellectual property protection for our products or avoid or defend claims ofinfringement;•the performance of third-party manufacturers and suppliers;•the potential effects of government regulation;•our ability to hire and retain key personnel and to manage our future growth effectively;•our ability to obtain additional financing in future offerings;•the volatility of the trading price of our common stock; and•our expectations regarding the period during which we qualify as an